Meningiomas are the most common primary intracranial neoplasms in adults. Despite their prevalence, their biologic underpinnings remain incompletely described. The recent application of unbiased next-generation sequencing and epigenomic approaches has implicated a new array of candidate biomarkers and oncogenic drivers. These insights may serve to craft a molecular taxonomy for meningiomas and highlight putative therapeutic targets in an era of biology-informed precision medicine.
Copyright © 2016 Elsevier Inc. All rights reserved.